IKT Inhibikase Therapeutics, Inc.

Inhibikase Therapeutics, Inc. operates as a clinical stage pharmaceutical company that is engaged in developing therapeutics for neurodegenerative disease inside and outside of the brain. The company develops IkT-148009, a brain penetrant c-Abl protein kinase inhibitor which is under phase I trial for Parkinson's disease (PD) and to treat early-stage PD patients with GI complications, as well as for the treatment of dysphagia and neurogenic constipation. Its clinical development product includes IkT-001Pro, an Abl kinase inhibitor prodrug of the anticancer agent for chronic myelogenous leukemia; and research phase products include IkT-01427 for progressive multifocal leukoencephalopathy, as well as IKT-148X to treat dementia with lewy body and multiple system atrophy. The company has collaborations with The Johns Hopkins University; Louisiana State University School of Medicine, Shreveport; the M. D. Anderson Cancer Center; and Memorial Sloan-Kettering Cancer Center. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia with additional offices in Boston, Massachusetts.  This company has other shares of common stock that are publicly traded. See the "related symbols" tab.

As of 11/30/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/23/2020
Outstanding shares:  25,155,198
Average volume:  338,989
Market cap:   $51,819,708
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    45719W106
ISIN:        US45719W1062
Valuation   (See tab for details)
PE ratio:   -4.89
PB ratio:   1.24
PS ratio:   13.65
Return on equity:   -29.17%
Net income %:   -331.63%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy